Market Overview

Morgan Stanley Looks Over Celgene's Quarter

Share:
Related CELG
Following ASH Conference, Vetr Upgrades Celgene
8 Of The Biggest Biotech Announcements Out Of The 2016 ASH Meeting
S&P 500, Dow Notch All-Time Highs; Dave & Buster's Soars 19% (Investor's Business Daily)

In a report published Friday, Morgan Stanley analysts maintained an Equal-Weight rating on Celgene Corporation (NASDAQ: CELG), while raising the price target from $109 to $110, after the company's quarterly results reflected in-line Revlimid and weakness across the rest of the portfolio.

The company announced quarterly revenue of $2.08B, short of expectations. However, the EPS was higher, at $0.01, with the beat being driven by

Revlimid (+$10M) sales were roughly in-line with consensus, while Abraxane (-$19M), Pomalyst/Imnovid (-$13M), and Otezla (-$12M) missed expectations.

Celgene reiterated its total revenue guidance for 2015 at $9.00-$9.50B, while projecting non-GAAP EPS at $4.60-$4.75, Revlimid sales of $5.60-$5.70B, Abraxanesales of $1-$1.25B, and operating margins at ~52 percent.

In the report Morgan Stanley noted "tidbits from the call":

  1. -$22M of the-$27M top-line f/x headwind was from Revlimid. The q/q f/x impact on Revlimid was -$10M
  2. The unhedged to-pline f/x impact was -5.8 percent
  3. The company said Revlimid sales may reach or exceed the upper end of the guidance range ($5.6-$5.7B)
  4. R&D is expected to increase through the year on account of "increasing collaboration and clinical costs"
  5. 85 percent of the $7.3B cash balance is ex-US
  6. Mgt. expects Abraxane sales to meet the lower end of range ($1-$1.25B)
  7. Mgt. indicated that Revlimid in "newly diagnosed MM had similar trends in Germany to what it saw in the early US launch."
  8. Early data indicate "Otezla persistence is similar to psoriasis analogues in the space"
  9. Otezla has received incremental share by "patients transitioning more quickly from methotrexate - a positive sign
  10. On GED-0301, Mgt. highlighted the presentations at DDW with a sub-analysis on patient reported outcomes and response by baseline level of disease activity

Latest Ratings for CELG

DateFirmActionFromTo
Nov 2016OppenheimerInitiates Coverage OnOutperform
Nov 2016Standpoint ResearchDowngradesBuyHold
Nov 2016MizuhoInitiates Coverage OnBuy

View More Analyst Ratings for CELG
View the Latest Analyst Ratings

Posted-In: Morgan StanleyAnalyst Color Price Target Reiteration Analyst Ratings

 

Related Articles (CELG)

View Comments and Join the Discussion!